Virus and pill combo takes on recurrent brain tumors

NCT ID NCT06264388

Recruiting now Disease control Sponsor: Ashish Shah Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests a two-part treatment for people with recurrent high-grade gliomas, a serious brain cancer. The treatment uses a virus (DB107-RRV) injected into the tumor and a chemotherapy pill (DB107-FC) taken by mouth. The goal is to shrink tumors and slow disease progression. The study enrolls 33 adults aged 18-75 whose cancer has returned after prior treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DB107-RRV (a virus that targets cancer cells) and DB107-FC (a chemotherapy pill)
What this could lead to: If it works, this could offer a new way to control recurrent high-grade gliomas, potentially shrinking tumors and extending survival.
What could go wrong: This is an early Phase 2 trial with only 33 participants, so results may not apply to all patients. The treatment involves brain surgery and virus injections, which carry risks like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC ASTROCYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaplastic astrocytoma astrocytoma (excluding glioblastoma) glioblastoma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAPLASTIC ASTROCYTOMA HIGH GRADE GLIOMA

Contacts and locations

Locations

University of Miami Hospital
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.